I think there is good opportunity with what’s going on at CHM. Leslie is on the CHM board and I don’t think it is to just make up the numbers. The science that is being developed there in my view is definitely a candidate for combination with CF33 if successful. I think Leslie is following the science. It is too much of a connection for me to ignore, so I have a holding in CHM as well, purely for CDH17 development.
Ann: Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia, page-76
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
